Heterologous adenovirus A2/Leish-Tec® vaccination strategy in a murine model of visceral leishmaniasis: Potential canine vaccine with enhanced protection and potent T-cell immunity.
Overall, the AdA2+LT heterologous strategy outperformed the other regimens and represents a promising vaccination approach against visceral leishmaniasis.